Anemia in inflammatory bowel disease: An under-estimated problem?

Frontiers in Medicine

Volumn 2, Issue JAN, 2015, Pages

  Rogler, Gerhard ^a   Vavricka, Stephan ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Anemia; Inflammatory bowel disease; Iron desorption

Indexed keywords

EID: 85061958264     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00058     Document Type: Review

References (87)

1. Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol (2014) 20(13):3542-51. doi: 10.3748/wjg.v20.i13.3542
2. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis (2014) 20(5):936-45. doi:10.1097/01.MIB.0000442728.74340.fd
3. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther (2006) 24(11-12):1507-23. doi:10.1111/j.1365-2036.2006.03146.x
4. Hoffbrand AV, Stewart JS, Booth CC, Mollin DL. Folate deficiency in Crohn's disease: incidence, pathogenesis, and treatment. Br Med J (1968) 2(5597):71-5. doi:10.1136/bmj.2.5597.71
5. Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology (1977) 73(4 Pt 1):828-32
6. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis (2006) 12(2):123-30. doi:10.1097/01.MIB.0000196646.64615.db
7. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology (2011) 141(3):846-53. doi:10.1053/j.gastro.2011.06.005
8. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med (1997) 126(10):782-7. doi:10.7326/0003-4819-126-10-199705150-00006
9. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med (1996) 334(10):619-23. doi:10.1056/NEJM199603073341002
10. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, et al. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther (2012) 35(1):133-41. doi:10.1111/j.1365-2036.2011.04914.x
11. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis (2001) 7(3):250-5. doi:10.1097/00054725-200108000-00011
12. Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis (2010) 4(6):642-8. doi:10.1016/j.crohns.2010.07.008
13. Ott C, Liebold A, Takses A, Strauch UG, Obermeier F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract (2012) 2012:595970. doi:10.1155/2012/595970
14. Ormerod TP. Anaemia in ulcerative colitis. Proc R Soc Med (1968) 61(9):931
15. Ormerod TP. Radio-iron (59Fe) studies in acute ulcerative colitis. Scand J Gastroenterol (1968) 3(2):189-92. doi:10.3109/00365526809180121
16. Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol (2013) 48(9):1027-32. doi:10.3109/00365521.2013.819442
17. Reinisch W, Staun M, Bhandari S, Munoz M. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. J Crohns Colitis (2013) 7(6):429-40. doi:10.1016/j.crohns.2012.07.031
18. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis (2012) 6(3):267-75. doi:10.1016/j.crohns.2011.09.010
19. Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail (2013) 15(10):1164-72. doi:10.1093/eurjhf/hft083
20. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol (2014) 174(2):268-75. doi:10.1016/j.ijcard.2014.03.169
21. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr (1986) 6:13-40. doi:10.1146/annurev.nu.06.070186.000305
22. Jacobs A. Non-haematological effects of iron deficiency. Clin Haematol (1982) 11(2):353-64
23. Lomer MC, Cook WB, Jan-Mohamed HJ, Hutchinson C, Liu DY, Hider RC, et al. Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease. Br J Nutr (2012) 107(12):1806-11. doi:10.1017/S0007114511004971
24. Oustamanolakis P, Koutroubakis IE, Kouroumalis EA. Diagnosing anemia in inflammatory bowel disease: beyond the established markers. J Crohns Colitis (2011) 5(5):381-91. doi:10.1016/j.crohns.2011.03.010
25. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Kefalogiannis G, Niniraki M, Kouroumalis EA. Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. J Crohns Colitis (2011) 5(4):295-300. doi:10.1016/j.crohns.2011.02.002
26. Oustamanolakis P, Koutroubakis IE, Messaritakis I, Niniraki M, Kouroumalis EA. Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Ann Gastroenterol (2011) 24(2):108-14
27. Alves RA, Miszputen SJ, Figueiredo MS. Anemia in inflammatory bowel disease: prevalence, differential diagnosis and association with clinical and laboratory variables. Sao Paulo Med J (2014) 132(3):140-6. doi:10.1590/1516-3180.2014.1323568
28. Bager P, Befrits R, Wikman O, Lindgren S, Moum B, Hjortswang H, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: a longitudinal 2-year follow-up study. Scand J Gastroenterol (2013) 48(11):1286-93. doi:10.3109/00365521.2013.838605
29. Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2010) 95(2):199-205. doi:10.3324/haematol.2009.009985
30. Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med (2013) 22(4):585-91
31. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett (2000) 480(2-3):147-50. doi:10.1016/S0014-5793(00)01920-7
32. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem (2001) 276(11):7806-10. doi:10.1074/jbc.M008922200
33. Canavesi E, Alfieri C, Pelusi S, Valenti L. Hepcidin and HFE protein: iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol (2012) 1(6):166-76. doi:10.5527/wjn.v1.i6.166
34. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 87(4):392-400. doi:10.1002/ajh.23110
35. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 1823(9):1434-43. doi:10.1016/j.bbamcr.2012.01.014
36. Nemeth E. Anti-hepcidin therapy for iron-restricted anemias. Blood (2013) 122(17):2929-31. doi:10.1182/blood-2013-08-522466
37. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol (2009) 122(2-3):78-86. doi:10.1159/000243791
38. Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci (2014) 35(3):155-61. doi:10.1016/j.tips.2014.01.004
39. Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab (2012) 15(6):905-17. doi:10.1016/j.cmet.2012.03.017
40. Qiao B, Sugianto P, Fung E, Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab (2012) 15(6):918-24. doi:10.1016/j.cmet.2012.03.018
41. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med (2011) 62:347-60. doi:10.1146/annurev-med-050109-142444
42. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta (2012) 1823(9):1426-33. doi:10.1016/j.bbamcr.2012.03.004
43. De Domenico I, Ward DM, Kaplan J. Hepcidin and ferroportin: the new players in iron metabolism. Semin Liver Dis (2011) 31(3):272-9. doi:10.1055/s-0031-1286058
44. Oates PS. The role of hepcidin and ferroportin in iron absorption. Histol Histopathol (2007) 22(7):791-804
45. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood (2003) 101(7):2461-3. doi:10.1182/blood-2002-10-3235
46. Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica (2011) 96(12):1761-9. doi:10.3324/haematol.2011.048926
47. Lambert LA. Molecular evolution of the transferrin family and associated receptors. Biochim Biophys Acta (2012) 1820(3):244-55. doi:10.1016/j.bbagen.2011.06.002
48. Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis (2009) 18(3):345-52
49. Feelders RA, Kuiper-Kramer EP, van Eijk HG. Structure, function and clinical significance of transferrin receptors. Clin Chem Lab Med (1999) 37(1):1-10. doi:10.1515/CCLM.1999.001
50. Worthen CA, Enns CA. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front Pharmacol (2014) 5:34. doi:10.3389/fphar.2014.00034
51. Fertrin KY, Lanaro C, Franco-Penteado CF, de Albuquerque DM, de Mello MR, Pallis FR, et al. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. Am J Hematol (2014) 89(4):385-90. doi:10.1002/ajh.23649
52. Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol (2009) 21(4):425-9. doi:10.1097/MEG.0b013e32830e2885
53. Basseri RJ, Nemeth E, Vassilaki ME, Basseri B, Enayati P, Shaye O, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis (2013) 7(8):e286-91. doi:10.1016/j.crohns.2012.10.013
54. Bergamaschi G, Di Sabatino A, Albertini R, Costanzo F, Guerci M, Masotti M, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis (2013) 19(10):2166-72. doi:10.1097/MIB.0b013e31829a6e43
55. Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P, et al. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis (2014) 8(11):1392-7. doi:10.1016/j.crohns.2014.04.008
56. Shanmugam NK, Trebicka E, Fu LL, Shi HN, Cherayil BJ. Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota. J Immunol (2014) 193(3):1398-407. doi:10.4049/jimmunol.1400278
57. Wang L, Trebicka E, Fu Y, Ellenbogen S, Hong CC, Babitt JL, et al. The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis (2012) 18(1):112-9. doi:10.1002/ibd.21675
58. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood (2010) 115(18):3810-6. doi:10.1182/blood-2009-02-201087
59. Lee P, Peng H, Gelbart T, Beutler E. The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A (2004) 101(25):9263-5. doi:10.1073/pnas.0403108101
60. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest (2004) 113(9):1271-6. doi:10.1172/JCI200420945
61. Bermejo F, Garcia-Lopez S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol (2009) 15(37):4638-43. doi:10.3748/wjg.15.4638
62. Guagnozzi D, Severi C, Ialongo P, Viscido A, Patrizi F, Testino G, et al. Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis (2006) 12(2):150-1. doi:10.1097/01.MIB.0000199223.27595.e3
63. Oustamanolakis P, Koutroubakis IE. Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflamm Bowel Dis (2011) 17(12):E158-9. doi:10.1002/ibd.21881
64. Przybyszewska J, Zekanowska E, Kedziora-Kornatowska K, Boinska J, Cichon R, Porzych K. Serum prohepcidin and other iron metabolism parameters in elderly patients with anemia of chronic disease and with iron deficiency anemia. Pol Arch Med Wewn (2013) 123(3):105-11
65. Park G, Park CY, Jang SJ, Moon DS, Park SM, Park YJ. Soluble transferrin receptor-ferritin index and estimated body iron in iron-deficiency anemia in "select" chronic diseases. Ann Hematol (2009) 88(9):913-5. doi:10.1007/s00277-008-0668-4
66. Berlin T, Meyer A, Rotman-Pikielny P, Natur A, Levy Y. Soluble transferrin receptor as a diagnostic laboratory test for detection of iron deficiency anemia in acute illness of hospitalized patients. Isr Med Assoc J (2011) 13(2):96-8
67. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem (1998) 44(1):45-51
68. Goyal R, Das R, Bambery P, Garewal G. Serum transferrin receptor-ferritin index shows concomitant iron deficiency anemia and anemia of chronic disease is common in patients with rheumatoid arthritis in north India. Indian J Pathol Microbiol (2008) 51(1):102-4. doi:10.4103/0377-4929.40417
69. Jain S, Narayan S, Chandra J, Sharma S, Jain S, Malhan P. Evaluation of serum transferrin receptor and sTfR ferritin indices in diagnosing and differentiating iron deficiency anemia from anemia of chronic disease. Indian J Pediatr (2010) 77(2):179-83. doi:10.1007/s12098-009-0302-z
70. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol (2011) 86(11):923-7. doi:10.1002/ajh.22108
71. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol (2012) 3(3):177-91. doi:10.1177/2040620712440071
72. Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol (2005) 84(3):159-66. doi:10.1007/s00277-004-0950-z
73. Brugnara C, Laufer MR, Friedman AJ, Bridges K, Platt O. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood (1994) 83(10):3100-1
74. Stoffman N, Brugnara C, Woods ER. An algorithm using reticulocyte hemoglobin content (CHr) measurement in screening adolescents for iron deficiency. J Adolesc Health (2005) 36(6):529. doi:10.1016/j.jadohealth.2004.09.011
75. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol (2011) 64(4):287-96. doi:10.1136/jcp.2010.086991
76. Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci (2009) 54(4):842-7. doi:10.1007/s10620-008-0436-2
77. Reinisch W, Chowers Y, Danese S, Dignass A, Gomollon F, Nielsen OH, et al. The management of iron deficiency in inflammatory bowel disease-an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther (2013) 38(9):1109-18. doi:10.1111/apt.12493
78. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol (2014) 89(6):646-50. doi:10.1002/ajh.23712
79. Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol (2013) 108(12):1877-88. doi:10.1038/ajg.2013.335
80. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol (2011) 23(11):1029-35. doi:10.1097/MEG.0b013e32834a58d1
81. Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med (2010) 268(3):286-95. doi:10.1111/j.1365-2796.2010.02251.x
82. Lindgren S, Wikman O, Befrits R, Blom H, Eriksson A, Granno C, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol (2009) 44(7):838-45. doi:10.1080/00365520902839667
83. Werner T, Hoermannsperger G, Schuemann K, Hoelzlwimmer G, Tsuji S, Haller D. Intestinal epithelial cell proteome from wild-type and TNFDeltaARE/WT mice: effect of iron on the development of chronic ileitis. J Proteome Res (2009) 8(7):3252-64. doi:10.1021/pr800772b
84. Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut (2011) 60(3):325-33. doi:10.1136/gut.2010.216929
85. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 13(12):1545-53. doi:10.1002/ibd.20285
86. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis (2006) 12(12):1101-6. doi:10.1097/01.mib.0000235097.86360.04
87. Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol (2014) 5:83. doi:10.3389/fphar.2014.00083